Last checked at 24 Sep 2020 12:54
For immediate release | 24 September 2020 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Board has issued options over an aggregate of 655,597 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below.
Peter Butterfield, Chief Executive Officer, has been awarded 165,500 unapproved share options under the Company's 2015 Share Option Plan; and, 246,269 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.
Andrew Franklin, Chief Financial Officer, has been awarded 110,000 unapproved share options under the Company's 2015 Share Option Plan; and, 134,328 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.
The share options awarded under the 2015 Company Share Option Plan have all been granted with an exercise price of 73.7p, being the closing mid-market price on 22nd September 2020, and become exercisable on 23rd September 2023, being the third anniversary of the date of the grant. The awards granted under the 2019 Long Term Incentive Plan have been granted at nil-cost and also become exercisable on 23rd September 2023.
The vesting of these awards is a subject to continued employment and the satisfaction of performance conditions based on EPS and TSR targets.
The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:
Name | Share Options granted | Total no. of options over ordinary shares now held |
Peter Butterfield | 411,269 | 3,200,453 |
Andrew Franklin | 244,328 | 1,853,511 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Mr Peter Butterfield | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive Officer - PDMR | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Alliance Pharma plc | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1.0 pence each
ISIN: GB0031030819 | |
b) | Nature of the transaction | Grant of Options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Exercise Price (p) | No. of share options |
73.7p | 165,000 | ||
Nil | 246,269 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 165,000 options to acquire shares at £0.737 per share at an aggregate exercise value of £121,605. Grant of 246,269 options to acquire ordinary shares of 1 pence each at nil-cost.
| |
f) | Date of the transaction | 23 September 2020 | |
g) | Place of the transaction | Outside of trading venue | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Mr Andrew Franklin | |
2 | Reason for the notification | ||
a) | Position/status | Chief Financial Officer - PDMR | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Alliance Pharma plc | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1.0 pence each
ISIN: GB0031030819 | |
b) | Nature of the transaction | Grant of Options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Exercise Price (p) | No. of share options |
73.7p | 110,000 | ||
Nil | 134,328 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 110,000 options to acquire shares at £0.737 per share at an aggregate exercise value of £81,070. Grant of 134,328 options to acquire ordinary shares of 1 pence each at nil-cost.
| |
f) | Date of the transaction | 23 September 2020 | |
g) | Place of the transaction | Outside of trading venue | |
For further information:
Alliance Pharma plc | + 44 (0)1249 466966 |
Peter Butterfield, Chief Executive Officer |
|
Andrew Franklin, Chief Financial Officer |
|
www.alliancepharma.co.uk |
|
Buchanan | + 44 (0)20 7466 5000 |
Mark Court / Hannah Ratcliff |
|
|
|
Numis Securities Limited | + 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Huw Jeremy |
|
Corporate Broking: James Black |
|
Investec Bank plc | + 44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams / Ed Thomas |
|
Corporate Broking: Patrick Robb / Tejas Padalkar |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com